PD-1/VEGF Program
Cancer (unspecified)
Not DisclosedActive
Key Facts
About OncoC4
OncoC4 is a private, clinical-stage biotech focused on novel immuno-oncology and neurodegenerative disease therapeutics. Its core strategy involves targeting both established (CTLA-4, PD-1) and emerging (CD24, Siglec) immune checkpoints with a pipeline of monoclonal antibodies, bispecifics, and antibody-drug conjugates. The company has established a key partnership with BioNTech for its lead CTLA-4 asset and operates with a lean, global team. OncoC4 is positioned in the competitive but high-potential fields of next-generation cancer immunotherapy and neuro-immunology.
View full company profileTherapeutic Areas
Other Cancer (unspecified) Drugs
| Drug | Company | Phase |
|---|---|---|
| Allogeneic CAR-NK Platform Product | Simnova Biotherapeutics | Phase 1 |
| CAR-engineered NK cells | Glycostem | Pre-clinical |
| Lead Universal CAR-T Candidate | Allogenica | Pre-clinical |
| ADU-1805 | Sairopa | Preclinical |
| PSC-derived NK Cells | HebeCell | Pre-clinical |
| mRNA CAR-γδ-T Cell Platform | PhosphoGam | Pre-clinical |
| R-5780 | Rise Therapeutics | Phase 1 |
| Dendritic Cell-Based Cancer Vaccines | Celica Biomedical | Pre-clinical |
| FC001 | FerroptoCure | Phase 1 |
| FC004 | FerroptoCure | Preclinical |
| Oncology Drug Delivery | Sporegen | Pre-clinical |